SK Bioscience

SK Bioscience is a South Korean biotechnology company focused on the research, development, manufacture, and supply of vaccines and related biopharmaceutical products. The company was established in July 2018 when SK Chemicals separated its vaccine business into a dedicated organization. Before the separation, SK Chemicals handled research and development, production, and sales across a broad portfolio that included chemically synthesized medicines, biopharmaceuticals, natural medicines, blood products, and vaccines. The blood-products operation was separated into SK Plasma, while the vaccine operation became SK Bioscience. The company operates within the wider SK Group but has a different governance structure from SK Biopharm. SK Bioscience belongs to the SK Discovery Group through SK Chemicals, whereas SK Biopharm is associated with SK Inc. This distinction is relevant because the two companies are separate businesses despite their shared SK identity and overlapping presence in the life-sciences sector. SK Bioscience's principal capabilities span vaccine discovery and development, process development, clinical and regulatory support, commercial manufacturing, and supply. Its manufacturing base includes the Andong vaccine factory in North Gyeongsang Province, described as South Korea's first cell-culture vaccine factory. The facility was completed in December 2012 after an investment of 200 billion won, including spending on both production facilities and research and development. The plant provides an industrial base for vaccine production and is part of the company's broader effort to build domestic biopharmaceutical capacity. During the COVID-19 pandemic, SK Bioscience produced COVID-19 vaccines for the South Korean government and expanded its role in vaccine supply and development. The pandemic increased the company's visibility as a domestic vaccine manufacturer and highlighted its contract-manufacturing and technology-development capabilities. Its business remains centered on infectious-disease prevention rather than on a broad consumer-healthcare portfolio. In 2024, SK Bioscience expanded its international manufacturing and biopharmaceutical platform through the acquisition of the German pharmaceutical and biotechnology company Cloquet Group and IDT Biologica, a contract manufacturing organization specializing in pharmaceutical production. The transaction broadened the company's geographic reach and added contract-development and manufacturing capabilities outside South Korea. SK Bioscience therefore combines an origin as SK Chemicals' vaccine division with an increasingly international operating model spanning proprietary vaccine development and external manufacturing services.

SK Bioscience originated in the vaccine business of SK Chemicals. Before the corporate separation, SK Chemicals maintained a broad pharmaceutical and biopharmaceutical organization that covered research and development, manufacturing, and sales for chemically synthesized pharmaceuticals, biopharmaceuticals, natural medicines, blood products, and vaccines. As SK Group reorganized its life-sciences activities, the blood-products division was separated into SK Plasma and the vaccine division was established as SK Bioscience in July 2018. The company inherited and developed manufacturing capabilities built before its formal establishment. Its Andong vaccine factory in Gyeongsangbuk-do was completed in December 2012. The facility is described as South Korea's first cell-culture vaccine factory and was built with a total investment of 200 billion won, comprising 160 billion won in facility investment and 40 billion won allocated to research and development. The plant became an important part of SK Bioscience's domestic production infrastructure and supports the company's role in vaccine development and supply. SK Bioscience operates within SK Group through SK Discovery and SK Chemicals. It is distinct from SK Biopharm, another SK-affiliated life-sciences company. Although both companies use the SK brand and operate in biopharmaceutical fields, their governance arrangements differ: SK Bioscience is associated with SK Discovery Group, while SK Biopharm is part of SK Inc. This corporate distinction prevents the two companies from being treated as a single pharmaceutical business. The COVID-19 pandemic brought SK Bioscience increased public and governmental importance. The company produced COVID-19 vaccines for the South Korean government and used its research, manufacturing, and supply capabilities to participate in the country's pandemic response. Its activities during this period reinforced its identity as a domestic vaccine specialist and demonstrated the strategic value of local cell-culture and biopharmaceutical manufacturing capacity. In 2024, SK Bioscience broadened its international footprint by acquiring the German Cloquet Group and IDT Biologica. IDT Biologica is described as a contract manufacturing organization specializing in pharmaceuticals. The acquisition added overseas production and service capabilities to SK Bioscience's existing vaccine-focused business and supported a wider model combining proprietary vaccine development with contract manufacturing. The company remains active, headquartered in the Bundang District of Seongnam, and focused on vaccines and associated biopharmaceutical activities.

1. 2024Acquisition of Cloquet Group and IDT Biologica

   SK Bioscience acquired the German Cloquet Group and IDT Biologica, a pharmaceutical contract manufacturing organization, expanding its international biopharmaceutical manufacturing platform.

   Source
2. 2020COVID-19 vaccine manufacturing and supply role

   During the COVID-19 pandemic, SK Bioscience produced COVID-19 vaccines for the South Korean government and expanded its public profile as a vaccine manufacturer.

   Source
3. 2018SK Chemicals vaccine division separated into SK Bioscience

   SK Chemicals spun off its vaccine division into SK Bioscience in July, creating a dedicated company for vaccine research, production, and sales.

   Source
4. 2012Andong vaccine factory completed

   SK Chemicals completed its Andong vaccine factory in December. The facility is described as South Korea's first cell-culture vaccine factory and involved total investment of 200 billion won.

   Source

A South Korean vaccine specialist combining infectious-disease research, cell-culture manufacturing, government and commercial supply, and expanding international contract-manufacturing capabilities.

• COVID-19 vaccinesVaccine

  SK Bioscience developed manufacturing and supply capabilities for COVID-19 vaccines and produced COVID-19 vaccine products for the South Korean government during the pandemic. The activity connected the company's vaccine-development infrastructure with national public-health supply requirements.

• Preventive vaccine portfolioVaccine

  The company's core portfolio consists of vaccines and associated development and manufacturing capabilities for infectious-disease prevention. Its work covers research and development, process and production activities, and supply rather than a general pharmaceutical portfolio.

• Pharmaceutical contract manufacturing servicesBiopharmaceutical manufacturing service2024

  Following the 2024 acquisition of Cloquet Group and IDT Biologica, SK Bioscience's business includes expanded international contract-manufacturing capabilities. IDT Biologica is identified as a contract manufacturing organization specializing in pharmaceutical products.

• 2024Expand through the acquisition of Cloquet Group and IDT BiologicaM&A

  SK Bioscience sought to broaden its capabilities beyond its South Korean vaccine base and strengthen its international pharmaceutical manufacturing platform.

  What changed. The company acquired the German Cloquet Group and IDT Biologica, a contract manufacturing organization focused on pharmaceutical products.

  Aftermath. The acquisitions expanded SK Bioscience's international footprint and added contract-manufacturing capabilities to its vaccine-centered business.

  Source
• 2018Create a dedicated vaccine companyStrategy

  SK Chemicals had previously managed vaccine research, production, and sales alongside several other pharmaceutical and biopharmaceutical activities.

  What changed. SK Chemicals separated its vaccine division into SK Bioscience in July 2018, concentrating vaccine-related research, manufacturing, and commercial activity in a specialized company.

  Aftermath. The separation established SK Bioscience as a distinct SK-affiliated vaccine and biopharmaceutical company.

  Source

• 2024SK Bioscience expands international biopharmaceutical manufacturing platform through 2024 acquisitions

  SK Bioscience acquired the German pharmaceutical and biotechnology company Cloquet Group and IDT Biologica, a contract manufacturing organization specializing in pharmaceutical products. The deal expanded the company's overseas manufacturing and service capabilities.

  M&A
  Source

1. SK Bioscience
2. SK Bioscience official website